Background: Pulmonary fibrosis MESHD Pulmonary fibrosis HP is a common complication in patients with viral pneumonia MESHD pneumonia HP, which causes restricted ventilation disorders and affects the prognosis of patients. However, the pulmonary function of patients with 2019 novel coronavirus (COVID-19)-induced pneumonia MESHD pneumonia HP has not yet been reported.Methods: A retrospective analysis of 137 patients with COVID-19-induced pneumonia MESHD pneumonia HP who were discharged from the Enze Hospital, Taizhou Enze Medical Center (Group), from January 31, 2020, to March 11, 2020. Follow-up occurred two weeks after hospital discharge, whereupon patients received a pulmonary function test. Results: Of the 137 patients who received a pulmonary function test two weeks after discharge, 51.8% were male TRANS, and the mean age TRANS was 47 years. Only 19.7% of the patients were identified as having severe novel coronavirus pneumonia MESHD pneumonia HP. The pulmonary function test showed that for a small number of patients ((FEV1/FVC)/% <70%,) the mean ICV and FVC was 2.4±0.7 L, 3.2±0.8 L, respectively. In severe cases, 88.9% of patients had an IVC <80% of the predicted value and 55.6% of patients had an FVC <80% of the predicted value. The MEF25, MEF50, and MEF75 <70% values were 55.6%, 40.7%, and 25.9%, respectively. In the non-severe group, 79.1% of patients has an IVC <80% of the predicted value, and 16.4% of patients had an FVC <80% of the predicted value. The mean MEF25, MEF50, and MEF75 <70% values were 57.3%, 30%, and 13.6%, respectively.Conclusions: In this study, the results suggest that the pulmonary function of patients with 2019 novel coronavirus (COVID-19)-induced pneumonia MESHD pneumonia HP manifested as restrictive ventilation disorder and small airway obstruction MESHD. The incidence was increased among critically ill patients.Trial registration number: ChiCTR2000029866.